The National Institute of Mental Health (NIMH) Initiative, Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS™), was designed to stimulate the development of psychopharmacological agents to improve cognition in schizophrenia and other related disorders. The BIFCA grew out of this initiative and was developed to meet the U.S. Food and Drug Administration’s requirement for a co-primary outcome measure for cognition-enhancing drugs for schizophrenia. The development process included:
- Sponsorship by a government-industry-academic collaboration (MATRICS™-CT)
- Consensus process and collection of empirical data
- Demonstrated relationship to cognitive deficits and functional outcomes
- Multiple studies investigating psychometric properties and cross-cultural adaptability of co-primary measures.
- Subtests selected for their interpretability across cultures
- Convenient administration, easy to include with other outcome measures
The development process is described in more detail in the following articles.
- Green, M.F., Schooler, N.R., Kern, R.S., Frese, F.J., et al. Evaluation of Functionally Meaningful Measures for Clinical Trials of Cognition Enhancement in Schizophrenia.
- Velligan, D.I., Rubin, M., Fredrick, M.M., Mintz, J., et al. The Cultural Adaptability of Intermediate Measures of Functional Outcome in Schizophrenia.
- Velligan, D.I., Fredrick, M., Mintz, J., Li, X., et al. The Reliability and Validity of the MATRICS Functional Assessment Battery.
- Comprehension and planning
- Household management
- Work and productivity
Through standardized performance-based simulations of daily activities, individuals demonstrate their:
- Capacity to plan
- Capacity to identify problems and generate solutions
- Ability to persist in an activity
– Simplified Chinese
– Spanish – Central and South America
– Spanish – Spain